Tempus announces its first-ever, whole-genome sequencing assay, xh

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xh. this test marks tempus' first foray into adopting whole-genome sequencing (wgs) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
TEM Ratings Summary
TEM Quant Ranking